unknown
Stage
1
Investors
About
Bonsai Biotherapeutics is a Sweden-based biotech company developing protein-based therapeutics that restore immune tolerance to self-proteins in autoimmune diseases such as myasthenia gravis (MG) and ANCA-associated vasculitis. Its lead candidate, TOL2 for MG, is composed of modified versions of the targeted proteins and is expected to enter a placebo-controlled clinical trial in 2026.
Explore Bonsai Biotherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.